SAN FRANCISCO, Aug. 30, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges DexCom, Inc. (NASDAQ: DXCM) investors who suffered substantial losses to submit your losses now. The firm also encourages persons with knowledge who may be able to assist in the investigation to contact its attorneys. Class Period: Jan. 8, 2024 – July 25, 2024Lead Plaintiff Deadline: Oct. 21, 2024Visit: www.hbsslaw.com/investor-fraud/DXCM Contact the Firm Now: DXCM@hbsslaw.com  844-916-0895 DexCom, Inc. (DXCM) Securities Class Action: D ...

RADNOR, Pa., Aug. 30, 2024 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against DexCom, Inc. ("DexCom") (NASDAQ: DXCM) on behalf of investors who purchased or otherwise acquired DexCom securities between January 8, 2024 to July 25, 2024, inclusive (the "Class Period") The lead plaintiff deadline is October 21, 2024.CONTACT KESSLER TOPAZ MELTZER & CHECK, LLP:If you suffered DexCom losses, you may CLIC ...

NEW YORK, Aug. 30, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against DexCom, Inc. (NASDAQ: DXCM) and certain of the Company’s senior executives. If you invested in DexCom, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/dexcom-inc. Investors have until October 21, 2024 to ask the Court to be appointed to lead the case. The complaint asserts claims under Sections 10(b) and ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In DexCom To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $100,000 in DexCom between January 8, 2024 to July 25, 2024 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, Aug. 29, 2024 (GLOBE NEWS ...

NEW YORK, Aug. 29, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of DexCom, Inc. (NASDAQ: DXCM).Shareholders who purchased shares of DXCM during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/dexcom-inc-loss-submission-form/?id=98720&from=4CLASS PERIOD: January 8, 2024 to July 25, 20 ...

NEW YORK, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against DexCom, Inc. (NASDAQ: DXCM) and certain of the Company’s senior executives. If you invested in DexCom, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/dexcom-inc. Investors have until October 21, 2024 to ask the Court to be appointed to lead the case. The complaint asserts claims under Sections 10(b) and ...

LOS ANGELES, Aug. 27, 2024 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming October 21, 2024 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired DexCom, Inc. (“DexCom” or the “Company”) (NASDAQ: DXCM) securities between January 8, 2024 to July 25, 2024, inclusive (the “Class Period”). If you suffered a loss on your DexCom investments or would like to inquire about potentially pursuing claims t ...

DexCom Inc. (DXCM) recently announced the availability of Stelo, the first over-the-counter (OTC) continuous glucose monitoring (CGM) biosensor in the United States. The biosensor is available for purchase without a prescription at Stelo.com.Dexcom glucose biosensors are a vital and effective tool for managing diabetes as they produce good clinical results independent of medication use and may even be able to slow down the disease's progression. Glucose biosensors, such as Stelo, can increase the efficacy o ...

NEW YORK, Aug. 27, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of DexCom, Inc. (NASDAQ: DXCM). Shareholders who purchased shares of DXCM during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/dexcom-inc-loss-submission-form/?id=98153&from=3 CLASS PERIOD: January 8, 2024 to Jul ...

Core Viewpoint - DexCom, Inc. is facing a class action securities lawsuit due to alleged securities fraud that affected investors between January 8, 2024, and July 25, 2024 [1][2] Group 1: Lawsuit Details - The lawsuit aims to recover losses for DexCom investors following the company's announcement of its second-quarter financial results on July 25, 2024, which included a reduction in revenue guidance for the full fiscal year 2024 [2] - DexCom attributed its disappointing results and lowered guidance to the execution of "several key strategic initiatives" that "did not meet [their] high standards" [2] - Following the announcement, DexCom's stock price plummeted from $107.85 per share on July 25, 2024, to $64.00 per share on July 26, 2024, marking a decline of approximately 40.66% in just one day [2] Group 2: Next Steps for Investors - Investors who suffered losses in DexCom during the specified timeframe have until October 21, 2024, to request to be appointed as lead plaintiff in the lawsuit [2] - Participation in any potential recovery does not require serving as a lead plaintiff [2] Group 3: Legal Representation - Levi & Korsinsky, LLP, the firm representing the investors, has a history of securing hundreds of millions of dollars for shareholders and is recognized as one of the top securities litigation firms in the United States [3]